Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07286032 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
A Phase 3 study, sponsored by Jiangsu HengRui Medicine Co..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07286032 is a Phase 3 study that is actively recruiting participants, run by Jiangsu HengRui Medicine Co.. The registered enrollment target is 150 participants.
The verdict
NCT07286032, a Phase 3 study, is actively recruiting participants, sponsored by Jiangsu HengRui Medicine Co..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
Interventions
- DRUG Hetrombopag Olamine
- DRUG Hetrombopag Olamine ；Hetrombopag Olamine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-04-16 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07286032
The ClinicalTrials.gov registry entry for NCT07286032 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jiangsu HengRui Medicine Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hetrombopag Olamine is the first listed.
NCT07286032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07286032 about?
NCT07286032 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia". The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.
What is the current status of trial NCT07286032?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-04-16. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07286032?
The interventions under investigation include: Hetrombopag Olamine (DRUG), Hetrombopag Olamine ；Hetrombopag Olamine Placebo (DRUG).
Who is sponsoring clinical trial NCT07286032?
This trial is sponsored by Jiangsu HengRui Medicine Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.